Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.50 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL368124 | 0.74 | AKR1C1 (0.54) | AKR1C1PRMT1ESR1CA12CA1 | |
| SCHEMBL55433 | 0.74 | ESR1 (0.74) | AKR1C1PRMT1ESR1CYP19A1CYP11B2 | |
| SCHEMBL3296981 | 0.74 | AKR1C1 (0.74) | AKR1C1PRMT1ESR1ALDH1A1LMNA | |
| SCHEMBL389392 | 0.74 | AKR1C1 (0.54) | AKR1C1PRMT1ESR1CA12CA1 | |
| SCHEMBL80025 | 0.74 | AKR1C1 (0.74) | AKR1C1PRMT1ESR1ALDH1A1LMNA | |
| SCHEMBL8065888 | 0.74 | CA12 (0.48) | CA12CA1CA2CA3CA4 | |
| SCHEMBL918848 | 0.74 | AKR1C1 (0.54) | AKR1C1PRMT1ESR1CA12CA1 | |
| Hydrochloric Acid SCHEMBL28642233 | 0.72 | ESR1 (0.71) | AKR1C1PRMT1ESR1CYP19A1CYP11B2 | |
| SCHEMBL28473756 | 0.72 | ALDH1A1 (0.43) | AKR1C1PRMT1ESR1ALDH1A1TSHR | |
| SCHEMBL30366689 | 0.72 | ESR1 (0.71) | AKR1C1PRMT1ESR1CYP19A1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112533934-B | Polyoxometallate compounds exhibiting bright emissions and methods of making same | 纳米2D材料有限公司 | 2024-07-19 | — | — | CN | disclosed |
| EP-4333982-A1 | PKC-THETA MODULATORS | Exscientia Al Limited (GB) | 2024-03-13 | — | — | EP | disclosed |
| CN-117384071-A | Synthesis method of hydroxy thioether compound | 江南大学 | 2024-01-12 | — | — | CN | disclosed |
| EP-3887370-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| CN-112533934-A | Polyoxometallate compounds exhibiting bright emission and methods of making the same | 纳米2D材料有限公司 | 2021-03-19 | — | — | CN | disclosed |
| WO-2020109190-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-04 | — | — | WO | disclosed |
| CN-107973791-B | Fused or tricyclic aryl pyrimidine compounds as kinase inhibitors | 南京圣和药业股份有限公司 | 2020-04-07 | — | — | CN | disclosed |
| CN-107614503-B | Fused or tricyclic aryl pyrimidine compounds as kinase inhibitors | 广东众生药业股份有限公司 | 2020-03-10 | — | — | CN | disclosed |
| EP-3290419-B1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) | 2019-08-07 | — | — | EP | disclosed |
| EP-3312179-B1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | NANJING SANHOME PHARMACEUTICAL CO LTD (CN) | 2019-07-10 | — | — | EP | disclosed |
| US-20180354953-A1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-12-13 | — | — | US | disclosed |
| US-10093656-B2 | Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor | NANJING SANHOME PHARMACEUTICAL CO., LTD (CN) | 2018-10-09 | — | — | US | disclosed |
| EP-3312179-A1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-25 | — | — | EP | disclosed |
| US-20180072704-A1 | Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-15 | — | — | US | disclosed |
| EP-3290419-A1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-07 | — | — | EP | disclosed |
| EP-0794218-B1 | Polycarbonate resin composition stabilized against radiation | MITSUBISHI ENG PLASTICS CORP (JP) | 2003-10-15 | — | — | EP | disclosed |
| US-6040367-A | EXCELLENT RESISTANCE TO AN IONIZING RADIATION, IN WHICH HETEROCYCLIC COMPOUND CONTAINING OXYMETHYLENE UNITS | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 2000-03-21 | — | — | US | disclosed |
| US-5948838-A | 0.01 TO 5 PARTS BY WEIGHT OF A COMPOUND CONTAINING OXYMETHYLENE UNIT | MITSUBISHI ENGINEERING-PLASTICS CORP. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0794218-A2 | Polycarbonate resin composition stabilized against radiation | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 1997-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072704-A1 | Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor | EGFR, ERBB2, ERBB4 | AKR1C1 2849/4885PRMT1 2575/4885ESR1 650/4885 |
| US-10093656-B2 | Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor | EGFR, ERBB2, ERBB4 | AKR1C1 2849/4885PRMT1 2575/4885ESR1 650/4885 |
| US-20180354953-A1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | EGFR, ERBB2, ERBB4 | AKR1C1 2849/4885PRMT1 2575/4885ESR1 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.